The global market for contract manufacturing of oral solid dosage forms was valued at USD 36.50 billion in 2023. This market is poised for significant growth, with projections indicating a compound annual growth rate (CAGR) of 5.97% from 2024 to 2030.

Several factors contribute to this growth. Firstly, there is an increasing focus on drug delivery technology, particularly targeted drug delivery and sustained-release dosage forms. Secondly, contract development and manufacturing organizations (CDMOs) are investing heavily in expanding their capabilities in oral solid dosage development. Lastly, the rising demand for novel therapies is driving the need for efficient and reliable manufacturing processes. 

Gather more insights about the market drivers, restrains and growth of the Oral Solid Dosage Contract Manufacturing Market

While oral pharmaceutical products are currently dominant, emerging technologies like 3D printing have the potential to revolutionize the industry. By enabling precise control over drug release and customization of dosage forms, 3D printing can address specific patient needs. This technology also allows for the production of complex shapes and formulations, offering greater flexibility in drug design and manufacturing. Consequently, the expansion of solid dose pharmaceutical manufacturing is closely linked to the development of innovative solid dose formats and increased efficiency.

Advancements in controlled-release technologies are also driving growth. These technologies improve drug delivery by providing sustained- and extended-release options, which enhance therapeutic efficacy and patient compliance. Additionally, the adoption of digital technologies and data analytics in oral solid dosage manufacturing is transforming the industry. By enabling enhanced process monitoring, quality control, and efficiency, these technologies empower contract manufacturers to provide transparent and data-driven solutions. Such advancements are expected to create significant growth opportunities in the market.

Product Segmentation Insights

The tablet segment, representing 32.7% of the market in 2023, is the dominant force due to its cost-effectiveness. This segment is projected to experience significant growth driven by increasing demand and technological advancements like continuous manufacturing and 3D printing. Companies like The Technology House (TTH) are at the forefront of this trend, having acquired an SLA 750 3D printer to enhance manufacturing efficiency and expand service offerings.

The capsules segment is expected to witness robust growth at a CAGR of 6.44% over the forecast period. Factors like ease of swallowing, faster disintegration, and absorption contribute to the segment's appeal. Technological advancements, such as liquid capsule filling technology adopted by Pace Life Sciences and Division of Pace, further propel market growth by expanding filling capabilities and accommodating diverse formulations. 

Order a free sample PDF of the Oral Solid Dosage Contract Manufacturing Market Intelligence Study, published by Grand View Research.